NCT00109993已完成2 期
Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 11
- 主要终点
- Graft-vs-host disease response
研究概览
简要总结
RATIONALE: Alemtuzumab, tacrolimus, and methylprednisolone may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant.
PURPOSE: This phase II trial is studying how well giving alemtuzumab together with tacrolimus and methylprednisolone works in treating acute graft-versus-host disease in patients who have undergone donor stem cell transplant.
详细描述
OBJECTIVES:
Primary
- Determine the 4-week rate of complete response in patients with severe acute graft-vs-host disease (GVHD) treated with alemtuzumab, tacrolimus, and methylprednisolone within 100 days after undergoing allogeneic stem cell transplantation.
Secondary
- Determine the best response at 4 and 12 weeks in patients treated with this regimen.
- Determine 6-month survival of patients treated with this regimen.
- Determine the rate of infectious complications in patients treated with this regimen.
- Determine rate of chronic GVHD in patients treated with this regimen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Graft-vs-host disease response
时间窗: 1, 2, 3, and 4 months
次要结局
- Incidence of serious infections by clinical, radiologic, and microbiologic assessments(1,2,3, and 4 months)
研究者
研究点 (11)
Loading locations...
相似试验
已完成
2 期
Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantationChronic Myeloproliferative DisordersGraft Versus Host DiseaseMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative DiseasesLymphomaLeukemiaNCT00096096Fred Hutchinson Cancer Center
已完成
2 期
Alemtuzumab Induction in Islet TransplantationType 1 DiabetesNCT00175253University of Alberta12
已完成
2 期
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell TransplantChronic Myeloproliferative DisordersGestational Trophoblastic TumorGraft Versus Host DiseaseMultiple Myeloma and Plasma Cell NeoplasmBreast CancerLymphomaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative DiseasesTesticular Germ Cell TumorOvarian CancerNeuroblastomaLeukemiaNCT00410657Fred Hutchinson Cancer Center53
进行中（未招募）
2 期
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3a Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Grade 1 Follicular LymphomaRefractory Grade 2 Follicular LymphomaRefractory Grade 3a Follicular LymphomaRefractory Mantle Cell LymphomaRefractory Marginal Zone LymphomaRefractory Small Lymphocytic LymphomaNCT04659044Academic and Community Cancer Research United63
已完成
2 期
Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation PatientsLiver TransplantationLiver DiseaseNCT00105235National Institute of Allergy and Infectious Diseases (NIAID)27